Filgrastim ELISA Kit (Antibody screening) Quantitative

Product type:
Biosimilar ELISA


Anti-Filgrastim ADA Quantitative ELISA Kit

Enzyme-linked immunosorbent assay for the quantitative determination of specific antibodies to Filgrastim in human serum and plasma with confirmation reagent (for 20 samples). The Assay Genie anti-filgrastim ELISA Kit is intended for the quantitative determination of Filgrastim anti-drug antibodies in serum and plasma. It is for professional use only.

Anti-Filgrastim ADA Quantitative ELISA Kit test principle

The Assay Genie Antibody to Filgrastim ELISA is a sandwich assay for the determination of anti-filgrastim antibodies in serum and plasma samples. During the first incubation period, the drug filgrastim coated on the wall of the microtiter wells captures the antibodies to filgrastim in patient serum and plasma samples. After washing away the unbound components from samples, a Peroxidase-labelled conjugate (which detects IgG, IgM, IgA and IgE antibodies) is added to each well and then incubated. After a second washing step, the bound enzymatic activity is detected by addition of tetramethylbenzidine (TMB) chromogen-substrate. Finally, the reaction is terminated with an acidic stop solution. The intensity of the reaction colour is directly proportional to the concentration of anti-filgrastim antibodies in a sample.

Anti-Filgrastim ADA Quantitative ELISA Product Information

Information Description
Free drug
Required Volume (μl)
Total Time (min)
Sample Type
Serum, Plasma
Number of Assays
Detection Limit (ng/mL)
3 (ng/mL)
Spike Recovery (%)
Shelf Life (year)
6 Months

Alternative Names

Granulocyte Colony Stimulating Factor (G-CSF)

Anti-Filgrastim ADA Quantitative ELISA - Key Information

Filgrastim mode of action

Filgrastim is a recombinant, non-pegylated human granulocyte colony stimulating factor (G-CSF) analogue manufactured by recombinant DNA technology using a strain of E. coli. Chemically, it consists of 175 amino acid residues. The protein has an amino acid sequence that is identical to the natural sequence predicted from human DNA sequence analysis, except for the addition of an N-terminal methionine necessary for expression in E coli. Filgrastim binds to the G-CSF receptor and stimulates the production of neutrophils in the bone marrow. As a GCSF analog, it controls proliferation of committed progenitor cells and influences their maturation into mature neutrophils. Filgrastim also stimulates the release of neutrophils from bone marrow storage pools and reduces their maturation time. Filgrastim acts to increase the phagocytic activity of mature neutrophils.

Filgrastim uses

In patients receiving cytotoxic chemotherapy, Filgrastim can accelerate neutrophil recovery, leading to a reduction in duration of the neutropenic phase. Filgrastim is used in patients with acute myeloid leukemia receiving induction or consolidation chemotherapy. It is also used in cancer patients receiving bone marrow transplant. In general, filgrastim increases neutrophil counts in order to decrease the risk of infection or duration of neutropenia. Neutropenia is an adverse event associated with chemotherapy. Filgrastim is also indicated for patients with severe chronic neutropenia. It mobilizes hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis to allow for a more rapid engraftment.

Filgrastim treatment

Used in the treatment of chemotherapy-induced neutropenia by enhancing the production of neutrophils. Filgrastim acts on hematopoietic cells by binding to specific cell surface receptors thereby stimulating proliferation, differentiation, commitment, and end cell functional activation. When filgrastim was administered to cancer patients, it took 3-5 days to reach maximum absolute neutrophil count (ANC). Levels of neutrophils returned to baseline by 21 days following completion of chemotherapy. In the healthy volunteer trials, doubling the filgrastim subcutaneous dose from 5 to 10 mcg/kg resulted in a 16-19% increase in the ANC max and a 33-36% increase in the area under the effect curve for ANC.

Filgrastim immunogenicity

As with any biologic therapeutic, immunogenicity, in the form of anti-filgrastim antibodies can occur. The demonstration of anti-filgrastim antibodies during treatment with filgrastim is a major concern. The Assay Genie Anti-Filgrastim ADA Quantitative ELISA Kit can be efficiently used for monitoring anti-filgrastim antibodies in biological samples and is for research use only.

Anti-Filgrastim ADA Quantitative ELISA Kit Contents

Size Kit Contents

1 x 12 x 8

Microtiter Plate

Break apart strips. Microtiter plate with 12 rows each of 8 wells coated with reactant

8 x 0.3 mL

Filgrastim Standards A-F (10X), High Level Control, Low Level Control

500; 250; 125; 62.5; 31.25; 0 ng/mL
Ready to use. Used for construction of the standard curve. Contains human serum, antibody to filgrastim, and <0.1% NaN3.

1 x 30 mL

Assay Buffer
Blue coloured. Ready to use. Contains proteins and <0.1% NaN3.

1 x 12 mL

Peroxidase Conjugate
Red coloured. Ready to use. Contains peroxidase (POD) conjugate, stabilizer and preservatives.

1 x 12 mL

TMB Substrate Solution
Ready to use. Contains TMB

1 x 12 mL

TMB Stop Solution
Ready to use. 1N HCl

1 x 50 mL

Wash Buffer concentrate (20x)
Contains Buffer with Tween 20.

2 x 1

Adhesive Foil
For covering of Microtiter Plate during incubation.

1 x 210 µL

Confirmation Reagent (For 20 Samples)
Ready to use. Contains optimized concentration of the filgrastim and <0.1% NaN3.

Anti-Filgrastim ADA Quantitative ELISA Protocol

Steps Protocol


Dilute each of the standards and samples (serum/plasma) using Assay Buffer as described in
“Dilution of Standards and Samples (serum/plasma)” section


Pipette 100 µL of each Diluted Standards, High Level Control, Low Level Control or diluted Serum
Samples into the respective wells of microtiter plate.

A1: Standard A
B1: Standard B
C1: Standard C
D1: Standard D
E1: Standard E
F1: Standard F
G1: High Level Control
H1: Low level Control
A2 and on: Sample (serum/plasma)


Cover the plate with adhesive foil. Incubate 60 min at room temperature (18- 25°C).


Remove adhesive foil. Discard incubation solution. Wash plate 3 times each with 300µL of diluted. Wash Buffer. Remove excess solution by tapping the inverted plate on a paper towel.


Pipette 100 µL of ready-to use Peroxidase Conjugate into each well.


Cover the plate with adhesive foil. Incubate 60 min at room temperature (18- 25°C).


Remove adhesive foil. Discard incubation solution. Wash plate 3 times each with 300 µL of diluted Wash Buffer. Remove excess solution by tapping the inverted plate on a paper towel.


Pipette 100 µL of TMB Substrate Solution into each well.


Incubate 20 min (without adhesive foil) at room temperature (18-25°C) in the dark


Stop the substrate reaction by adding 100 µL of Stop Solution into each well. Briefly mix contents by gently shaking the plate. Colour changes from blue to yellow.


Measure optical density with a photometer at 450/650 nm within 30 min after pipetting of the Stop Solution.


NEUPOGEN® is the Amgen Inc. trademark for filgrastim

View AllClose